EditorialThe tightening grip of big pharma
References (0)
Cited by (24)
The pharmaceutical industry as an informant
2002, LancetCitation Excerpt :Possibilities include inherent biases in trial design,15 for instance, by use of inappropriate comparator drugs,15,16 drug doses,16,17 or methods to assess outcomes.18,19 Occasionally, in attempts to ensure a positive bias, companies have threatened legal action to stop nominally independent researchers from publishing negative material.20–23 Moreover, researchers who communicate negative results have faced intimidation, efforts to discredit them professionally, and threats of legal action to recover the value of lost sales.24
The clinical trial: Deceitful, disputable, unbelievable, unhelpful, and shameful - What next?
2001, Controlled Clinical TrialsMedical malpractice, murder and the academic community: Trouble ahead
2001, International Journal of Cardiology"BIG PHARMA" IN OUR BEDROOMS: AN ANALYSIS OF THE MEDICALIZATION OF WOMEN'S SEXUAL PROBLEMS
2003, Advances in Gender Research
Copyright © 2001 Elsevier Ltd. All rights reserved.